1. Home
  2. VYGR vs RCEL Comparison

VYGR vs RCEL Comparison

Compare VYGR & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYGR
  • RCEL
  • Stock Information
  • Founded
  • VYGR 2013
  • RCEL N/A
  • Country
  • VYGR United States
  • RCEL United States
  • Employees
  • VYGR N/A
  • RCEL N/A
  • Industry
  • VYGR Biotechnology: Pharmaceutical Preparations
  • RCEL Medical/Dental Instruments
  • Sector
  • VYGR Health Care
  • RCEL Health Care
  • Exchange
  • VYGR Nasdaq
  • RCEL Nasdaq
  • Market Cap
  • VYGR 164.3M
  • RCEL 161.5M
  • IPO Year
  • VYGR 2015
  • RCEL N/A
  • Fundamental
  • Price
  • VYGR $3.20
  • RCEL $5.42
  • Analyst Decision
  • VYGR Strong Buy
  • RCEL Strong Buy
  • Analyst Count
  • VYGR 8
  • RCEL 4
  • Target Price
  • VYGR $14.33
  • RCEL $16.50
  • AVG Volume (30 Days)
  • VYGR 715.4K
  • RCEL 316.4K
  • Earning Date
  • VYGR 08-05-2025
  • RCEL 08-07-2025
  • Dividend Yield
  • VYGR N/A
  • RCEL N/A
  • EPS Growth
  • VYGR N/A
  • RCEL N/A
  • EPS
  • VYGR N/A
  • RCEL N/A
  • Revenue
  • VYGR $66,958,000.00
  • RCEL $71,661,000.00
  • Revenue This Year
  • VYGR N/A
  • RCEL $57.16
  • Revenue Next Year
  • VYGR $78.88
  • RCEL $36.69
  • P/E Ratio
  • VYGR N/A
  • RCEL N/A
  • Revenue Growth
  • VYGR N/A
  • RCEL 41.35
  • 52 Week Low
  • VYGR $2.65
  • RCEL $4.71
  • 52 Week High
  • VYGR $9.55
  • RCEL $14.16
  • Technical
  • Relative Strength Index (RSI)
  • VYGR 51.88
  • RCEL 43.61
  • Support Level
  • VYGR $2.83
  • RCEL $5.11
  • Resistance Level
  • VYGR $3.43
  • RCEL $5.55
  • Average True Range (ATR)
  • VYGR 0.19
  • RCEL 0.31
  • MACD
  • VYGR 0.01
  • RCEL 0.10
  • Stochastic Oscillator
  • VYGR 55.22
  • RCEL 69.61

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: